ARTHEx Biotech

We would like to congratulate Victor Ambros and Gary Ruvkun for receiving the 2024 #NobelPrize in Medicine for their discovery of microRNA and its role in post-transcriptional gene regulation! We applaud the recognition of microRNA and its important role in gene expression and regulation, which supports the scientific founding of ARTHEx Biotech – we are inspired by this and energized to continue developing innovative medicines through the modulation of gene expression to treat myotonic dystrophy type 1 and other genetically-driven diseases. Read more here: https://lnkd.in/g8-xG_b Photo credit: https://lnkd.in/g8-xG_b #NobelPrize2024 #RNAInnovation #MicroRNA #Biotech The Nobel Prize

In partnership with the Myotonic Dystrophy Foundation, we invite you to attend Drs. beatriz llamusi and Judith Walker’s presentation on Friday, October 4th at 3:00 pm EDT. Join us to learn more about ATX-01, the industry’s first anti-microRNA therapeutic to be investigated for Myotonic Dystrophy (DM). Register here to attend: https://lnkd.in/eUQ5j9XF #MyotonicDystrophy #biotech #microRNA

Frederic LEGROS, our Chairman and CEO, is excited to participate in Chardan's 8th Annual Genetic Medicines Conference, which will take place from Monday, September 30th, to Tuesday, October 1st, in New York. Take this opportunity to meet with Dr. Frédéric Legros in a one-on-one session to discuss our pipeline and our therapeutic approach to leveraging microRNA modulation for the treatment of myotonic dystrophy type 1. Learn more here: https://lnkd.in/gZQ3vPjt #CGMC2024 #ChardanGMConf #MyotonicDystrophy #Biotechnology Chardan

Yesterday marked International Myotonic Dystrophy Awareness Day, and at ARTHEx Biotech, our commitment to raising awareness about Myotonic Dystrophy (DM) continues—today and every day! Our team proudly showed their support by wearing green, standing in solidarity with the DM community. Myotonic Dystrophy is a rare, multi-systemic, and inherited condition that progresses across generations, making it the most common form of adult muscular dystrophy. Yet, despite its prevalence, DM is often misdiagnosed, under-supported, and tragically, there are still no approved treatments or cures available. We invite you to join us in our mission to advocate for better support and brighter futures for those affected by DM. Together, we can make a difference! #MyotonicDystrophy #MyotonicDystrophyAwareness #SupportDM Myotonic Dystrophy Foundation

Frederic LEGROS, our Chairman & CEO is excited to participate in the Barclays Biotech: 1x1 Private Company Symposium, taking place August 7, 2024. He will participate in virtual one-on-one meetings with potential investors during the conference. . Learn more here: https://lnkd.in/gUd7Xb83 #Biotechnology #MyotonicDystrophy

The ARTHEx Biotech team is proud to sponsor the upcoming CureDM Myotonic Dystrophy Family Weekend community event, organized by the Cure Myotonic Dystrophy UK Charity (Cure DM). This annual event, beginning on July 26th, will take place at Legoland Windsor to bring together families living with DM while having fun, too. Learn more here: www.curedm.co.uk #CureDMCharity #CureDM #CommunityEvent #MyotonicDystrophy #Biotechnology

Meet Nuria Barquero, DVM, MSc, PhD, ERT, our Head of Nonclinical Toxicology at ARTHEx Biotech! A Canadian native who moved to Spain at age 2.5, Nuria's love for science began early in her life. For the past 25 years, she has immersed herself in the field, accumulating a wealth of experience in academia and industry across Spain, the USA, and the UK. Reflecting on her career, Nuria takes sound advice from Laura Manuelidis of Yale University: "Science must be reproducible." This mantra underscores the importance of meticulous record-keeping, as even small changes can significantly affect experiment outcomes and reproducibility. Outside the office, Nuria finds joy in the company of her supportive husband and four beautiful children. When not immersed in family time, you'll likely find her outdoors, indulging in her love for reading, cooking, and various outdoor activities. Learn more about ARTHEx here: https://lnkd.in/d_DTXkh3 #EmployeeSpotlight #Biotechnology #MyotonicDystrophy

ARTHEx Biotech is honored to have been awarded the prestigious EIC grant from the EIC Accelerator funding program under Horizon Europe. This grant recognizes our commitment to making a difference in the lives of those with rare conditions by developing innovative treatments tailored to patients’ specific needs.   This grant will be used to support our Phase I/IIa clinical trial of ATX-01 for the treatment of Myotonic Dystrophy Type 1, or DM1.     Learn more about our approach and pipeline here: https://lnkd.in/drWXTU6Z #MyotonicDystrophy #biotech #financing #microRNA

ARTHEx Biotech is attending BioEquity Europe on May 12-14, 2024 in San Sebastian, Spain. Our Chairman and CEO, Frederic LEGROS, will also access the one-on-one partnering system to engage with potential investors during the conference. Click here to send us a meeting request: https://lnkd.in/ghTsFt4x Click here to learn more about the meeting: https://lnkd.in/dzunkQc #Biotechnology #MyotonicDystrophy #BioEquityEurope